- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Pegozafermin, a potential treatment for improving fibrosis in NASH patients: Phase 2b Trial
USA: The positive outcomes of a phase 2b trial support the further advancement of pegozafermin into phase 3 trials for NASH treatment. If successful, pegozafermin could provide a much-needed therapeutic option for patients with NASH and potentially improve their long-term liver health.
The phase 2b clinical trial presented at the European Association for the Study of the Liver (EASL) Congress 2023 has demonstrated promising results for pegozafermin as a potential treatment for nonalcoholic steatohepatitis (NASH) patients with fibrosis.
The trial, simultaneously published in The New England Journal of Medicine, showed that more than 1-in-4 patients receiving 30 mg and 44 mg doses of pegozafermin met the criteria for fibrosis improvement, compared to only 7% in the placebo group. The parent company, 89 bio, has expressed plans to discuss the advancement of pegozafermin into phase 3 trials for NASH with regulatory agencies in the second half of 2023.
● The primary outcomes of interest were fibrosis improvement with no worsening of NASH at 24 weeks and NASH resolution without worsening of fibrosis at 24 weeks.
● Fibrosis improvement was defined as a reduction of at least one stage.
● The results showed that the proportion of patients achieving fibrosis improvement was significantly higher in the pegozafermin groups compared to the placebo group.
● Specifically, 26% of patients in the 30 mg pegozafermin group and 27% in the 44 mg pegozafermin group met the criteria for fibrosis improvement, compared to 7% in the placebo group.
● NASH resolution was also observed in a higher percentage of patients receiving pegozafermin compared to placebo.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751